This publication summarises a recent presentation delivered by Professor David Bushinsky at a Sanofisponsored educational event on 22 April 2015 in Melbourne, Australia. Professor Bushinsky is a Professor of Medicine and of Pharmacology and Physiology at the University of Rochester School of Medicine, and Chief, Nephrology Division, University of Rochester Medical Center, Rochester, New York.
He addressed renal physicians about the available treatment options and controversy surrounding the management of hyperphosphataemia in stage 5 chronic kidney disease.
Please login below to download this issue (PDF)